← Leaderboards
Doug Cress
University Of South Florida
$1,912,333
Attributed
$2,384,030
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $622.5K · FY2008–14$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$2,384,030 · 4
By mechanism
P50$1,453,268 · 1
U54$628,929 · 2
R01$301,833 · 1
Top collaborators
- Jaime L Matta4 shared
- Teresita Munoz-Antonia4 shared
- Jose A Torres-Ruiz4 shared
Most similar at University Of South Florida
Same institution · by research overlap
- Warren Jackson Pledger$8,054,101
- Susan C McMillan$6,102,529
- Wenlong Bai$2,481,550
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsPlayCancer PatientResearch StudyCell CycleMalignant Neoplasm Of LungMolecularProteinsSamplingBaseNon-Small-Cell Lung CarcinomaDeacetylaseE2f1 GeneDrug UsageCytotoxicContrast MediaCytotoxic AgentEtoposideCisplatinCessation Of LifeChemotherapeutic AgentChemotherapyBinding (Molecular Function)Clinical Research
Grant awards (10)
Molecular Biology of Lung Cancer among Puerto Ricans$205,662
U54 · FY2014 · CA · contact PI
Molecular Biology of Lung Cancer among Puerto Ricans$200,789
U54 · FY2013 · CA · contact PI
P1 - E2F's impact on Therapeutic Efficacy$400,000
P50 · FY2012 · CA · contact PI
Molecular Biology of Lung Cancer among Puerto Ricans$111,240
U54 · FY2012 · CA · contact PI
Molecular Biology of Lung Cancer among Puerto Ricans$111,238
U54 · FY2012 · CA · contact PI
P1 - E2F's impact on Therapeutic Efficacy$280,049
P50 · FY2011 · CA · contact PI
P1 - E2F's impact on Therapeutic Efficacy$316,733
P50 · FY2010 · CA · contact PI
E2F's impact on Therapeutic Efficacy$301,620
P50 · FY2009 · CA · contact PI
E2F's impact on Therapeutic Efficacy$154,866
P50 · FY2008 · CA · contact PI
FACS High Throughout Screening of Hematopoiesis$301,833
R01 · FY2003 · EB